---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-023380"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2023-05-22T23:59:59+00:00"
generated_at: "2026-06-14T18:26:27.759031+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences reports Q1 net income of $6.2M; cash $17.7M; IND work ongoing

## Summary
- Q1 2023 net income $6.2M ($2.79 basic EPS) vs net loss $6.6M in Q1 2022; driven by $7.7M warrant liability gain.
- Cash and equivalents $17.7M at March 31, 2023, up from $5.3M at Dec 31, 2022; net cash used in ops $1.6M.
- Management expects existing cash to fund operations through June 2024.
- IND and clinical enabling studies for REVTx-300 and REVTx-100 underway; Phase 1 start targeted Q4 2023.
- Decreased clinical study expenses due to completion of prior Phase 2b and Phase 1b studies.

## SEC filing metadata
- accession: 0000950170-23-023380
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2023-05-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017023023380/0000950170-23-023380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017023023380/revb-20230522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-023380
- JSON: https://secwatch.observer/filing/0000950170-23-023380.json
- Plain text: https://secwatch.observer/filing/0000950170-23-023380.txt

## Key facts
- Earnings Releases
  REVELATION BIOSCIENCES, INC. reported three months ended March 31, 2023 results: net income $6.2 million, EPS $2.79 basic earnings per share and $1.96 diluted earnings per share.
  - Period: three months ended March 31, 2023
  - Net income: $6.2 million
  - EPS: $2.79 basic earnings per share and $1.96 diluted earnings per share
  - Result: reported results
  source text: Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017023023380/0000950170-23-023380-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.